Alliance Pharma plc Asset Resilience Ratio
Alliance Pharma plc asset resilience ratio. Alliance Pharma plc (APH) has an Asset Resilience Ratio of -0.43% as of December 2017. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Alliance Pharma plc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Alliance Pharma plc (2015–2017)
Asset resilience ratio of Alliance Pharma plc from 2015 to 2017. This chart shows how Alliance Pharma plc's Asset Resilience Ratio has changed over time. Read APH total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Alliance Pharma plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Alliance Pharma plc total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX-1.46 Million | -0.43% |
| Total Liquid Assets | GBX-1.46 Million | -0.43% |
Asset Resilience Insights
- Limited Liquidity: Alliance Pharma plc maintains only -0.43% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Alliance Pharma plc Industry Peers by Asset Resilience Ratio
Compare Alliance Pharma plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Alliance Pharma plc Asset Resilience Ratio by Year (2015–2017)
Alliance Pharma plc asset resilience ratio by year from 2015 to 2017. The table below shows the annual Asset Resilience Ratio data for Alliance Pharma plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | -0.43% | GBX-1.46 Million ≈ $-177.88 |
GBX336.48 Million ≈ $40.94K |
+0.02pp |
| 2016-12-31 | -0.46% | GBX-1.46 Million ≈ $-177.88 |
GBX320.74 Million ≈ $39.02K |
+0.04pp |
| 2015-12-31 | -0.50% | GBX-1.46 Million ≈ $-177.88 |
GBX292.19 Million ≈ $35.55K |
-- |
About Alliance Pharma plc
Alliance Pharma plc, a holding company, acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. It provides its products under the Aloclair, Anbesol, Asthon & Parsons, Forceval, Hydromol, Kelo-Cote, MacuShield, Vamousse, Nizoral, and Amberen brand names. The company was incorporated i… Read more